1. Home
  2. CGEN vs GLU Comparison

CGEN vs GLU Comparison

Compare CGEN & GLU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Compugen Ltd.

CGEN

Compugen Ltd.

HOLD

Current Price

$2.26

Market Cap

148.7M

Sector

Health Care

ML Signal

HOLD

Logo Gabelli Global Utility of Beneficial Ownership

GLU

Gabelli Global Utility of Beneficial Ownership

HOLD

Current Price

$19.91

Market Cap

119.8M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CGEN
GLU
Founded
1993
2004
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
148.7M
119.8M
IPO Year
2001
N/A

Fundamental Metrics

Financial Performance
Metric
CGEN
GLU
Price
$2.26
$19.91
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$4.00
N/A
AVG Volume (30 Days)
303.3K
11.1K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
8.60%
EPS Growth
N/A
N/A
EPS
N/A
0.62
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$58.57
N/A
P/E Ratio
N/A
$32.12
Revenue Growth
N/A
N/A
52 Week Low
$1.13
$14.07
52 Week High
$2.38
$21.69

Technical Indicators

Market Signals
Indicator
CGEN
GLU
Relative Strength Index (RSI) 63.91 34.50
Support Level $1.45 $17.65
Resistance Level $2.36 $20.17
Average True Range (ATR) 0.15 0.44
MACD 0.04 -0.20
Stochastic Oscillator 85.60 4.62

Price Performance

Historical Comparison
CGEN
GLU

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

About GLU Gabelli Global Utility of Beneficial Ownership

Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company. The Fund's objective is to seek a consistent level of after-tax total return. It predominantly invests in stocks of companies involved to a substantial extent in providing products, services, or equipment for the generation or distribution of electricity, gas, or water and infrastructure operations, and in equity securities including preferred securities of companies in other industries, in each case in such securities that are expected to pay periodic dividends.

Share on Social Networks: